key: cord-0863618-vrh8t817
authors: Butler, Matthew; Cross, Benjamin; Hafeez, Danish; Lim, Mao Fong; Morrin, Hamilton; Rengasamy, Emma Rachel; Pollak, Tom; Nicholson, Timothy R.
title: Emerging Knowledge of the Neurobiology of COVID-19
date: 2021-11-11
journal: Psychiatr Clin North Am
DOI: 10.1016/j.psc.2021.11.001
sha: a8eda3014238eec7c89a108e0a96cd18905e89b9
doc_id: 863618
cord_uid: vrh8t817

Many patients with COVID-19 will experience acute or longer-term neuropsychiatric complications. The neurobiological mechanisms behind these are beginning to emerge, however the neurotropic hypothesis is not strongly supported by clinical data. The inflammatory response to SARS-CoV-2 is likely to be responsible for delirium and other common acute neuropsychiatric manifestations. Vascular abnormalities such as endotheliopathies contribute to stroke and cerebral microbleeds, with their attendant neuropsychiatric sequelae. Longer-term neuropsychiatric syndromes fall into two broad categories: neuropsychiatric deficits occurring after severe (hospitalised) COVID-19, and ‘long COVID’, which occurs in many patients with a milder acute COVID-19 illness.

COVID-19, the syndrome caused by infection with the novel coronavirus SARS-CoV-2, has, at the time of writing, affected over 200 million people worldwide. 1 In mild COVID-19 illnesses, which constitute the large majority, viral replication tends to be confined to the upper respiratory tract, although in severe cases COVID-19 may affect multiple organs, including the central nervous system. 2 Indeed, high rates of neuropsychiatric complications in COVID-19 were expected based on data from previous coronavirus epidemics. 3 Large studies have indicated high rates of neurological and neuropsychiatric complications of COVID-19, which in the majority are non-specific and include fatigue, myalgia, depression, anxiety, and headache. 4 As well as these common neuropsychiatric complications, there are rarer central nervous system complications, such as encephalitis and, possibly, psychosis. 5, 6 In the acute phase of COVID-19, delirium is the most common neuropsychiatric manifestation, and is thought to arise secondary to the inflammatory response to SARS-CoV-2 replication. 7 Furthermore, cerebral vasculopathy secondary to the inflammatory response likely predisposes to complications ranging from acute infarctions (i.e. stroke) to subtle microvascular alterations. 8 Towards the beginning of the pandemic it was hypothesised that SARS-CoV-2 may be neurotropic: that is, able to directly invade and replicate inside neuronal cells. 9 The scientific community had good reason to suspect this, as SARS-CoV-2 was found to enter human host cells via the angiotensin-converting enzyme 2 (ACE-2), a transmembrane protein expressed by multiple tissue types across the body, including in the nasal neuroepithelium, where it is found in high levels. 10 Many patients with acute COVID-19 were found to experience anosmia, which in J o u r n a l P r e -p r o o f some cases is long-lasting, suggesting possible viral interference with the olfactory neurons, which may have represented a possible route of entry into the proximal central nervous system. 11 This hypothesis has been supported by preclinical data which has suggested that the virus is able to replicate inside laboratory simulations of central nervous system tissue, such as brain organoids, 12 as well as suggestions from some neuroimaging data. 13 There are, however, limits to the conclusions that can be drawn from these in vitro studies, and there has been very scant evidence of neurotropism from clinical and post-mortem studies. 9 Over the roughly eighteen months of the pandemic, the neurotropic hypothesis has gradually fallen out of favour, and there have been other, more nuanced, neurobiological hypotheses posited to explain the high rates of neuropsychiatric complications of COVID-19. 9 Many of these hypotheses implicate the immune response to the virus, which is likely to be responsible for many of the acute neuropsychiatric complications of the disorder, but is also a potential contributing factor to longer-term neuropsychiatric sequelae of COVID-19, 14 many of which are currently known as 'long COVID'. 15 Indeed, large numbers of patients with long COVID symptoms, ranging from persistent anosmia, to neurocognitive abnormalities, to persistent and disabling fatigue, will continue to suffer as a longer-term result of the pandemic. 2, 15 What follows is a broad discussion of the current neurobiological hypotheses on the aetiology and pathophysiology of both the acute and longer-term neuropsychiatric complications of COVID-19.

We discuss these mechanistic factors in relation to the commonest neuropsychiatric syndromes which arise in the context of COVID-19.

What are the mechanisms behind acute neuropsychiatric complications of COVID-19?

Delirium is a syndrome defined as an acute disturbance in attention and awareness, as well as impairment in other aspects of cognition such as memory or perception, which tends to fluctuate in severity over days or hours. In this manuscript we use delirium as the default term for such patients, reserving the term acute encephalopathy for clinical syndromes which incorporate rapidly-developing pathobiological brain processes with additional neurological signs or symptoms (for a consensus recommendation on this issue please see reference). 16 J o u r n a l P r e -p r o o f Delirium is common, and the incidence in elderly hospital inpatients has been estimated to be up to 35%. 17 Although the cause is often multifactorial, it is well established that infections and the resultant systemic inflammatory response may lead to delirium in predisposed individuals, perhaps through cytokine-induced cholinergic neurotransmitter deficiencies. 18 Data has indicated that many patients with COVID-19 experience delirium in the acute phase -in some populations up to half of all casesand in some delirium can be the sole presenting feature. 19 There is evidence demonstrating a higher prevalence of delirium in those with severe infection, 20 especially in those admitted to intensive care (ICU) 21 and in the elderly or those with dementia. 7 Despite this, delirium in COVID-19 has also affected those without typical risk factors for delirium, including younger patients. 22 Some have suggested that patients with COVID-19 may be at risk of a dysfunctional immune response mediated by massive cytokine release, known as a 'cytokine storm'. 23 Massive cytokine release is postulated as being responsible for multi-organ pathology in severe COVID-19, for example acute respiratory distress syndrome. Some patients have shown cytokine storm immune responses to other epidemic viruses, such as H1N1 influenza 24 and other coronaviruses. 25 Despite the theoretical risk of a cytokine storm, the data has not been consistently supportive of its common presence in COVID-19. 26 Whether or not COVID-19 patients experience cytokine storms, high levels of circulating inflammatory markers, as is seen in any immune response to an infectious pathogen, may lead to central nervous system complications such as delirium.

Patients with COVID-19 have also been shown to have high levels of circulating serum cytokines, such as interferon-gamma (IFN-γ) and IL-17, which suggest a pro-inflammatory T-helper type I (Th1) and Th17 immune response. 27 Pro-inflammatory cytokines, such as IL-6, IL-8 and tumour necrosis factor alpha (TNF-α), seen in severe COVID-19, 28 can interfere with blood-brain barrier (BBB) permeability via upregulation of cyclooxygenase-2 (COX-2) and activation of matrix metalloproteases. 29 This COVID-19 related BBB breakdown has been shown in both preclinical 30 and clinical research. 31 Disruption of the blood-brain barrier (BBB) may facilitate entry of inflammatory or immune mediators which induce or mediate neuroinflammation via microglial activation and T-cell invasion. 32 If severe enough this may lead to lasting neuronal damage and subsequent cognitive impairment. 33 J o u r n a l P r e -p r o o f

Depression has been reported at high levels in patients with acute COVID-19, although most studies to date have used basic screening tools in hospitalised patients, both of which are factors which may misrepresent true overall prevalence. 34 There are, of course, many reasons why a person with a severe respiratory pandemic illness may develop low mood or depression beyond the neurobiological effects of the infection. Nevertheless, it is possible that COVID-19 itself may directly lead to symptoms of depression, particularly as the risk of depressive symptoms may be increased with more severe COVID-19 illness. 35 The most plausible method of neurobiological depressogenesis in response to COVID-19 is via the a) inflammatory response, or b) as a result of cerebrovascular damage secondary to systemic endotheliopathy, post-stroke depression, or hypoxic brain injury.

Inflammatory cytokines have been postulated to cause depressive symptoms for decades, 36 and one evolutionary model of depression suggests that social withdrawal and 'forced rest', both symptoms which overlap with those seen in depression, are a useful adaptive response to an infection or injury. 37 There has been evidence to support the hypothesis: chronic inflammatory conditions such as rheumatoid arthritis are associated with high levels of depression, 38 and administration of proinflammatory cytokines (e.g. interferon-alpha (IFN-α) based immunotherapy in chronic hepatitis C) can induce depressive symptoms in humans and animals. 39 Some data has suggested that the degree of inflammation in COVID-19 is correlated with the extent of depressive symptoms, 40 although this has not always been replicated. 41 It remains to be established whether cytokines play a causal role in depressive illness in COVID-19 and other inflammatory conditions, or whether they simply represent epiphenomena without major significance (or, more likely, that the bidirectional relationship is complicated and not yet fully understood).

As has been noted, patients with COVID-19 are predisposed to cerebrovascular pathology, including acute stroke. 8 It is well-known that the incidence of depression is high following stroke. 42 Additionally, multiple neuroimaging studies in COVID-19 patients (typically severe cases) have consistently shown structural brain lesions, particularly in white matter tracts. 43 It is possible that this structural damage predisposes individuals to a depression in which vascular or structural changes are a contributing factor: a 'vascular depression'. The vascular depression hypothesis posits that cerebrovascular damage, or vascular insufficiency, leads to disruption in cerebral functioning, especially of frontostriatal circuits, which predispose to low mood. 44 J o u r n a l P r e -p r o o f Additionally, it was noted in previous coronavirus epidemics that cases of acute affective disorders, including mania, arose in the context of systemically administered corticosteroid (e.g. dexamethasone, prednisolone) therapy. 3 Following large randomised-controlled trials which supported their use, corticosteroids are now routinely prescribed to hospitalised COVID-19 patients. 45 Corticosteroids are known to cause a spectrum of neuropsychiatric side effects, including acute mania and depression, which occur in an estimated 6% of prescriptions. 46 The mechanisms by which steroids induce affective symptoms remain unclear, although disruptions to the hypothalamic-pituitary-adrenal (HPA) axis are commonly seen in depression, 47 and it is hypothesised that glucocorticoids may cause altered neurotransmitter and neuroreceptor gene transcription. 48 Nevertheless, despite these plausible assertions, there have only been sporadic reports of mania in hospitalised COVID-19 patients, 49 which have not been replicated in other samples. 4, 50 Psychosis Psychosis has long-been associated with viral illness, and as far back as the 17 th century, certain respiratory infections including influenza were linked with acute psychotic disorders. 51, 52 At the height of the 1918-19 Spanish Influenza pandemic, hundreds of reports of post-psychotic influenza were reported. 51 In COVID-19, the incidence of psychotic disorders is estimated at around 1%, rising to 3% for those with (ICU) admission and 7% in those with delirium. 56 The factors implicated in the genesis of psychotic symptoms in COVID-19 is likely to be multifactorial and centre around physiological and psychological stress. 6 An additional factor for consideration is the confounding of true psychotic symptoms by the presence of delirium. Psychotic features are often present in delirium, and diagnosis of a true psychotic disorder may be difficult or even impossible in the acute illness-phase. However, cases of psychosis published earlier in the pandemic have reported psychotic disorders in patients who have screened negative for delirium and without grossly abnormal inflammatory profiles. 49 Another important confounder may be the use of corticosteroids in treating COVID-19, which are well-documented to precipitate delirium and hallucinations. 46 In summary, despite substantial evidence for biological plausibility implicating SARS-CoV-2 in the generation of psychotic illnesses, a temporal, definitive association is far from proven, especially as potential confounders such as delirium and treatment side-effects are unaccounted for.

Nevertheless, immunopsychiatric research has implicated inflammatory processes in the development of psychosis, 53 and epidemiological studies have shown robust associations between viral infections and subsequent development of psychosis, either in childhood or via maternal infection in utero. 54, 55 A small subset of psychoses are autoimmune in origin, and the development of autoantibodies to receptors has been associated with acute viral infection.

Nevertheless, this represents a small subset of psychotic patients and the majority of patients tested will be negative for autoantibodies. 57 Cell or antibody-mediated post-infectious psychosis is therefore a potential, albeit likely rare, mechanism for the pathogenesis of COVID-19 psychosis.

Encephalitis is defined as inflammation of the brain parenchyma which occurs most often in response to pathogens, systemic inflammation, or autoimmune antibodies. 58 Encephalitis, as well as the related inflammatory syndrome of acute disseminated encephalomyelitis, 59 has been reported to occur in patients with COVID-19. 60 In order for cerebral inflammation to occur, either pathogens or inflammatory mediators (or both) must enter the central nervous system, for example via disruptions in the BBB. Although in theory this disruption could also allow for the migration of SARS-CoV-2 into the cerebral parenchyma infection (as seen in, for example, herpes simplex encephalitis), this has not yet been borne out by most data. 9 Instead, there are data suggesting the presence of anti-SARS-CoV-2 antibodies 31 as well as autoantibodies, such as anti-neuronal, 61 anti-glial, 61 and anti-NDMAR antibodies 61 

Patients with COVID-19 have been found to be susceptible to cerebrovascular pathology, including acute stroke. 8 Stroke occurs in approximately 1-3% of hospitalised COVID-19 patients, and 6% of those admitted to intensive care. 64 Stroke can result in significant neuropsychiatric J o u r n a l P r e -p r o o f complications, with around one-third of stroke survivors experiencing anxiety, depression or apathy. 65 COVID-19 associated strokes have been suggested to be more likely to present with large vessel occlusion, multi-territory involvement and involvement of otherwise uncommonly affected vasculature than is typically, with clinically observed neurological deficit typically being severe. 64 Although neuroimaging findings in COVID-19 have often been heterogenous and non-specific, 66 grey matter lesions occur most frequently in the temporal and precentral gyrus and bilateral thalamus, whilst white matter lesions occur most frequently in the corticospinal tract and corpus callosum. 43 Changes in thalamocortical connectivity have the potential to impair regulation of arousal and consciousness 67 and therefore may be responsible for observed symptoms such as agitation, disorientation, confusion and loss of consciousness. 68 Corpus callosum injury impairs interhemispheric communication, potentially causing disconnection syndrome with neurocognitive deficits. 43 Endotheliopathy (i.e., a disruption of endothelial cells responsible for maintaining vascular integrity) in COVID-19 has been identified as a substantial contributor to development of thrombotic complications such as stroke. 69 As SARS-CoV-2 particles infiltrate endothelial cells of the cerebral vasculature there is activation of macrophages, neutrophils, complement pathways, and thrombin production; together, these encouraging deposition of microthrombi. 70 Cerebral post-mortem studies demonstrate acute hypoxic-ischaemic injury from micro-and macro-infarcts, as well as haemorrhage and mild-to-moderate inflammation, 71 though correlation between histopathological findings and SARS-CoV-2 RNA in brain has been lacking. 72 Patients with severe COVID-19 are at risk of hypoxic-ischaemic brain injury both from the direct viral effects on pulmonary tissue, the inflammatory sepsis response (including hypotension), 73 as well as iatrogenic factors such as intubation. 74 Cerebral microhaemorrhages have also been reported in cases of patients with severe COVID-19 requiring intensive care. 75 It has been suggested that these may arise secondary to hypoxia-induced cerebral vasodilatation and release of cytokines, reactive oxygen species and vascular endothelial growth factor, as a similar pattern has been observed in individuals with non-COVID-19 related respiratory failure and critical illness. 76 Whilst the long-term effects of cerebral microhaemorrhages in COVID-19 patients are uncertain, in other disease independent association has been observed between microhaemorrhages and cognitive impairment and disability. 77 

What are the mechanisms behind the longer-term neuropsychiatric complications of COVID-19?

Many patients who are infected with COVID-19 will experience persistent neuropsychiatric symptoms such as sleep disturbance, fatigue, cognitive difficulties, anxiety, and post-traumatic stress symptoms, depression, and myalgia. 78 Although, as yet, there is no universally agreedupon definition for this syndrome which is thought to affect around 10% of COVID-19 survivors, it is currently most often referred to as long COVID. 15 The exact symptomology of Long-COVID is not yet clear with patients often reporting varied, relapsing-remitting symptoms, 79 Intuitively, we might expect to see long COVID overrepresented in patients who have been hospitalised by severe acute COVID-19. Indeed, in some studies, length of hospitalisation with COVID-19 has been identified as a predictor of greater impairment in functional status. 82 This indicates that prolonged symptoms which persist could in part demonstrate a broader post-ICU syndrome, a constellation of symptoms found in many patients following a critical illness, is driven by factors such as prolonged deconditioning and the stress of responding to a life-threatening illness. 83 The story, however, is a little more complex, and many suffer with debilitating long COVID symptoms which emerge after a relatively 'mild' acute COVID-19 illness; 2,78 indeed, on study found a correlation between a weaker anti-SARS-CoV-2 response and long COVID. 84 This indicates that long COVID is likely a heterogenous illness which includes a large proportion of patients who suffer with a phenotypical distinct entity to post-ICU syndrome. 78 One theory suggests that the neuroendocrine and inflammatory effects of infection can mediate symptoms of withdrawal and fatigue consistent with an evolutionary perspective emphasising the survival benefit gained from withdrawal to convalesce from a pathogenic illness (as discussed J o u r n a l P r e -p r o o f above). Furthermore, the physical and psychological exhaustion from the infection may lead to deconditioning, as was seen in severe acute respiratory syndrome (SARS, a coronavirus). 3 Initial attempts have been made to establish biomarkers which may help us understand the underlying pathophysiology of long COVID. In patients discharged from hospital, lymphopenia and elevated D-dimer and C-reactive protein levels were found in a minority. 14 This persistence of derangement in biomarkers, particularly those associated with inflammation, indicate that long COVID symptoms could be related to a lingering 'tail' and an abnormal inflammatory response to an infection. 85, 86 Some authors have suggested that long COVID symptoms may linger due to the prolonged presence of SARS-CoV-2 after the acute illness, partly as some data has indicated that SARS-CoV-2 RNA continues to be found in bodily fluids after the acute illness (particularly in stool samples), and that B-cell somatic hypermutations continue months after exposure, suggesting an ongoing and evolving immune response to a persistent virus. 87 Nevertheless, there is no consensus on this hypothesis, particularly as it has not previously been considered relevant in previous coronavirus infections, and the presence of viral RNA does not necessarily translate into clinical relevance. 88 Overall, firm evidence for the underlying neurobiology of Long COVID is unclear, and the literature lacks large-scale prospective studies. The evidence so far is mixed, indicating possible avenues for further exploration, for example whether increased inflammation during the infective phase of COVID-19 may predispose to more severe symptoms and that those with "long-COVID" may have high-normal levels of inflammatory markers which exacerbate their symptoms. These increased inflammatory markers may or may not interact with the nervous system to drive abnormalities and autonomic dysfunction which drive symptoms. 89 All of these physiological mechanisms must be seen in the biopsychosocial context where the experience of COVID-19 infection and its psychological effects may influence lingering symptoms.

Longer term neurocognitive impairment resulting from COVID-19 is likely to occur in some patients. Indeed, data from the SARS epidemic indicated that some hospitalised patients had impairments of memory, attention, concentration, or mental processing speed at one year followup. 3 This has been replicated in a number of studies in COVID-19, albeit many with shorter followup periods. 20, 90 Whether or not these cognitive abnormalities are specific to COVID-19 can be J o u r n a l P r e -p r o o f contested, as cognitive deficits following many severe illnesses requiring intensive care (ITU) admission are well-recognised. 91 Nevertheless, as with many other long COVID symptoms, data are suggesting that the degree of longer-term cognitive impairment is not always related to the severity of the acute COVID-19 illness. 92 Longer term neurocognitive syndromes following acute COVID-19 are likely to be seen in three distinct but overlapping patient groups: a) those with post-delirium cognitive impairment, driven by CNS inflammation, 40 b) those without preceding delirium, suggesting alternative mechanisms of cognitive deficit such as hypoxic brain insults, 93 and c) those with a milder course of illness with alternate mechanisms of cognitive impairment.

It is well-established that delirium is a risk factor for the subsequent development of neurocognitive impairment and dementia, and can precipitate a stepwise, irretrievable decline in cognition in people who already have a dementia diagnosis or with mild cognitive impairment. 94 This suggests that we may see a sharp increase in the incidence of dementia as a result of COVID-19 over the coming years.

Neurocognitive deficits post-discharge from COVID-19 illness have been associated with low blood oxygenation as well as the presence of acute respiratory distress syndrome (ARDS), which may indicate hypoxic brain insults in pathogenesis of persisting cognitive deficits. 90 It is known that medial temporal brain regions (including the hippocampus, which has a key role in short-term memory) are particularly sensitive to hypoxaemia, 95 and subtle neuroimaging changes across the brain including in the hippocampus have been found in patients who were hospitalised with severe COVID-19. 96 Other neuroimaging studies in COVID-19 have shown areas of brain hypometabolism in many brain regions, including limbic and paralimbic areas, brainstem, and cerebellum on 18 F-FDG positron emission tomography (PET) scans. The presence of these markers of brain hypometabolism have been associated with persistent cognitive abnormalities post-acute COVID-19 illness. 97 Finally, cognitive and attentional deficits, known by some as 'brain fog,' is a common feature of long COVID. 98 The mechanisms whereby these subjective cognitive changes arise have yet to be fully understood, and will likely be complex and multifactorial. Nevertheless, it is likely that a proportion of patients, particularly those in younger age demographics than typically affected by dementias, will have symptoms indicating functional cognitive disorder, which, as with any functional disorder, may arise from an acute physical illness such as COVID-19. Functional J o u r n a l P r e -p r o o f cognitive disorders cause distress and disability, however do not represent a degenerative brain disorder. 99 Similar functional cognitive symptoms have been seen in other conditions such as functional neurological disorder (FND), chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), and fibromyalgia. 100 In utero effects COVID-19 may adversely affect neonatal outcomes, with reported higher rates of foetal distress, low birth weight, intrauterine growth restriction, and increased rates of pre-term births. 101 Some have suggested that this may translate into increased risk of neurodevelopmental and neuropsychiatric disorders, although at present these hypotheses are speculative. 102 Maternal infection with other viruses (e.g. herpes simplex, rubella, poliovirus, Zika, and influenza) have been associated with increased risk of neurodevelopmental disorders, 103 including, for example, autism spectrum disorder (ASD). 104 Some of the strongest evidence linking maternal viral infections with schizophrenia to date is from the 1964 rubella pandemic, in which there was a 10 to 15-fold increased risk of schizophrenia spectrum disorders in offspring born to mothers who contracted the virus. 105 Mechanisms behind these putative effects are broadly two-fold: either via immune constituents or maternal hormones interacting with foetal neurogenesis. Elevated levels of IgG and IgM, which occur in viral infections, may cross into placental circulation, leading to disruption in neuronal development. 106 As has been noted, SARS-CoV-2 may elicit a Th17 (IL-17) immune response, and studies in mouse models have administration of IL-17 produces an autism-like phenotype and behaviour in offspring. 107 Similarly, the physiological, metabolic, and endocrine correlates of maternal physiological stress, which may occur in the context of a viral illness, have been noted to be associated with increased risk of neurodevelopmental outcomes in offspring, including ASD 103 and schizophrenia. 108 Whether or not these factors will be relevant to the offspring of COVID-19 positive mothers is not yet known. 109 

It has been well established that many patients with COVID-19 illness will develop neuropsychiatric complications. The neurobiology behind these acute complications is continuing to emerge, and emphasis is now placed upon inflammatory and parainfectious systemic effects of COVID-19 illness as opposed to direct viral neurotropism. Beyond the COVID-19 pandemic, J o u r n a l P r e -p r o o f research into this area may help to elucidate mechanisms by which other viral illnesses may contribute to illnesses such as psychosis, cognitive impairment, and CFS/ME. Many patients will experience long-lasting neuropsychiatric difficulties following COVID-19. These patients fall roughly into two distinct but overlapping groups; those who had a severe COVID-19 illness with acute neuropsychiatric complications, and those with 'milder' COVID-19 illnesses, who nevertheless have lasting neuropsychiatric effects. Finally, it has been speculated (though far from proven), that offspring born to mothers who had COVID-19 may be more at risk of neurodevelopmental conditions, principally autism spectrum disorder and schizophrenia spectrum disorders.

In clinical practice, patients can be reassured that it is most likely that the SARS-CoV-2 virus will not directly infect their central nervous system, however physicians be alert to the common neuropsychiatric manifestations. Delirium is particularly common, and in some patients will be the sole presenting syndrome of SARS-CoV-2 infections. Finally, patients should be strongly advised to follow public health advice on COVID-19 transmission and to receive a SARS-CoV-2 vaccination whenever possible, as this is the most effective way of reducing risk of neuropsychiatric complications associated with COVID-19.

J o u r n a l P r e -p r o o f

COVID-19 CORONAVIRUS PANDEMIC

Neuropsychiatric complications of covid-19

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

The neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Meningoencephalitis associated with COVID-19: a systematic review

COVID-19 and psychosis risk: Real or delusional concern?

Delirium in Older Patients With COVID-19 Presenting to the Emergency Department

Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors

Neurological infection with SARS-CoV-2 -the story so far

Angiotensin-converting enzyme 2 (ACE2) and the pathophysiology of coronavirus disease 2019

Smell and taste dysfunction in patients with COVID-19

Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids

Brain Imaging before and after COVID-19 in UK Biobank

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung

Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies

Delirium in elderly people

Systemic infection and delirium: when cytokines and acetylcholine collide

Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

Neurologic Features in Severe SARS-CoV-2 Infection

Delirium: A Frequent Manifestation in COVID-19 Older Patients

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Three fatal cases of pandemic 2009 influenza A virus infection in Shenzhen are associated with cytokine storm

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Is a "Cytokine Storm" Relevant to COVID-19?

Cytokine profile and disease severity in patients with COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier

Anti-SARS-CoV-2 antibodies in the CSF, bloodbrain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Systemic inflammation and delirium: important co-factors in the progression of dementia

The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis

Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults

The Role of Inflammation in Depression and Fatigue

The role of inflammation in depression: from evolutionary imperative to modern treatment target

Rheumatoid arthritis and depression: an inflammatory perspective

Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: A critical systematic review

Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up

Interleukin 6 and depression in patients affected by Covid-19. Med Clínica Engl Ed

Post-stroke depression

Modelling the Anatomic Distribution of Neurologic Events in Patients with COVID-19: A Systematic Review of MRI Findings

White matter hyperintensities in late life depression: a systematic review

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited

The HPA axis in major depression: classical theories and new developments

Central corticosteroid actions: Search for gene targets

Psychiatric presentation of patients with acute SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team

Reduced Activity in an Inpatient Liaison Psychiatry Service During the First Wave of the COVID-19 Pandemic: Comparison With 2019 Data and Characterization of the SARS-CoV-2 Positive Cohort. Front Psychiatry

Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk

Are some cases of psychosis caused by microbial agents? A review of the evidence

A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis

Childhood infection and adult schizophrenia: A meta-analysis of population-based studies

Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin

Neurological associations of COVID-19

Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 Infection: A Case Series

Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study

High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms

Do cross-reactive antibodies cause neuropathology in COVID-19?

Severe COVID-19-related encephalitis can respond to immunotherapy

Stroke in patients with COVID-19: Clinical and neuroimaging characteristics

Neuropsychiatric sequelae of stroke

Cerebral Imaging in Patients with COVID-19 and Neurological Symptoms: First Experience from two University Hospitals in Northern Germany

Neuroanatomic connectivity of the human ascending arousal system critical to consciousness and its disorders

Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

What can we learn from brain autopsies in COVID-19?

Microvascular Injury in the Brains of Patients with Covid-19

Critical illness: the brain is always in the line of fire

The 'third wave': impending cognitive and functional decline in COVID-19 survivors

Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19

Critical Illness-Associated Cerebral Microbleeds

Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI

Persistent Neuropsychiatric Symptoms after COVID-19: A Systematic Review and Meta-Analysis. Psychiatry and Clinical Psychology

Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine

Post-acute COVID-19 syndrome

Post-COVID-19 functional status six-months after hospitalization

Post-ICU syndrome: Rescuing the undiagnosed

Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study

The long tail of Covid-19' -The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients

Immunological Dysfunction Persists for 8 Months Following Initial Mild-Moderate SARS-CoV-2 Infection. Infectious Diseases (except HIV/AIDS)

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Decoding the unknowns in long covid

Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies

Long-Lasting Cognitive Abnormalities after COVID-19

Post-intensive care syndrome: impact, prevention, and management

Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal population cohort

COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. Di Gennaro F

The Prognostic Significance of Delirium in Older Hospital Patients

The hypoxic brain. Insights from ischemia research

Long-term micro-structure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations

18F-FDG brain PET hypometabolism in patients with long COVID

How COVID-19 Affects the Brain

Functional cognitive disorders: a systematic review

A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review

Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review

Maternal immune responses and obstetrical outcomes of pregnant women with COVID-19 and possible health risks of offspring

Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic

Maternal Infection Requiring Hospitalization During Pregnancy and Autism Spectrum Disorders

Nonaffective Psychosis After Prenatal Exposure to Rubella

Maternal Infections and Subsequent Psychosis Among Offspring

The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring

Higher Risk of Offspring Schizophrenia Following Antenatal Maternal Exposure to Severe Adverse Life Events

Conceived in the covid-19 crisis: impact of maternal stress and anxiety on fetal neurobehavioral development